Citius Pharmaceuticals, Inc. (CTXR)
$
0.71
+0.01 (1.41%)
Key metrics
Financial statements
Free cash flow per share
-0.1541
Market cap
7.2 Million
Price to sales ratio
46.3943
Debt to equity
0.0154
Current ratio
0.3684
Income quality
0.6619
Average inventory
14.9 Million
ROE
-0.6052
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company founded in 2007 and headquartered in Cranford, New Jersey, engages in the development and commercialization of critical care products with a focus on anti-infective solutions in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Currently, the company is advancing five proprietary products: Mino-Lok, an antibiotic lock solution aimed at treating catheter-related bloodstream infections by salvaging infected catheters; Mino-Wrap, a liquifying gel-based wrap designed to reduce tissue expander infections post-breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation targeting anti-inflammatory and anesthetic relief for hemorrhoid sufferers; NoveCite, a mesenchymal stem cell therapy intended for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein developed for patients with persistent or recurrent cutaneous T-cell lymphoma. The weighted average number of shares outstanding is 173,856,960.00 highlighting the company's shareholder base and its commitment to transparency. The company incurred an interest expense of $0.00 reflecting its debt servicing obligations. Moreover, the net income ratio is 0.00 indicating the company's profitability margin. Additionally, the net total of other income and expenses is $3,145,842.00 reflecting non-core financial activities, while the gross profit ratio is 0.00 demonstrating the efficiency of the company’s production and sales operations. In terms of market positioning, the stock is affordable at $0.71 making it suitable for budget-conscious investors. However, it has a low average trading volume of 303,385.00 indicating lower market activity which might appeal to specific investor profiles. With a market capitalization of $7,317,432.00 the company is classified as a small-cap player, which often attracts investors interested in growth opportunities. Citius Pharmaceuticals, Inc. is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, it belongs to the Healthcare sector, driving innovation and fostering growth in critical therapeutic areas that address pressing healthcare needs.
Is Citius Pharmaceuticals, Inc. (CTXR) a good investment?
Investing in Citius Pharmaceuticals, Inc. (CTXR) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Citius Pharmaceuticals, Inc. (CTXR)'s stock forecast?
Analysts predict Citius Pharmaceuticals, Inc. stock to fluctuate between $0.65 (low) and $26.25 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Citius Pharmaceuticals, Inc.'s market capitalization?
As of 2025-05-28, Citius Pharmaceuticals, Inc.'s market cap is $7,317,432, based on 10,290,300 outstanding shares.
How does Citius Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Citius Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Citius Pharmaceuticals, Inc. (CTXR) stock?
To buy Citius Pharmaceuticals, Inc. (CTXR) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CTXR. Place an order (Market, Limit, etc.).
What is the best time to invest in Citius Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Citius Pharmaceuticals, Inc. stock ever split?
Citius Pharmaceuticals, Inc.'s last stock split was 1:15 on 2017-06-09.
How did Citius Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.23 | Growth: 4.55%.
Where can I find Citius Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.citiuspharma.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Citius Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Citius Pharmaceuticals, Inc. stock?
All-time high: $114 (2021-06-22) | All-time low: $0.65 (2025-05-08).
What are the key trends affecting Citius Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
14 days ago
CRANFORD, N.J. , May 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal quarter ended March 31, 2025.
prnewswire.com
24 days ago
CEO Leonard Mazur to present on Thursday, June 5, 2025, at 3:10 pm ET CRANFORD, N.J. , May 5, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and its oncology subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), today announced that Leonard Mazur, Chairman and Chief Executive Officer of both companies, will present at the Jefferies Global Healthcare Conference, taking place June 3 – June 5, 2025 in New York City.
prnewswire.com
2 months ago
CRANFORD, N.J. , April 1, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into a definitive agreement for the purchase of 1,739,131 shares of its common stock (or pre-funded warrants in lieu thereof), at a purchase price of $1.15 per share (or pre-funded warrant in lieu thereof).
prnewswire.com
3 months ago
CRANFORD, N.J. , Feb. 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2024.
prnewswire.com
4 months ago
Permanent J-Code (J9161) expected to be effective April 1, 2025 LYMPHIR is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. CRANFORD, N.J.
prnewswire.com
5 months ago
CRANFORD, N.J. , Jan. 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive agreements for the purchase of an aggregate of 743,496 shares of its common stock and accompanying warrants to purchase up to an aggregate of 743,496 shares of its common stock, at a purchase price of $4.035 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.
prnewswire.com
5 months ago
CRANFORD, N.J. , Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL).
prnewswire.com
5 months ago
CRANFORD, N.J. , Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.
prnewswire.com
5 months ago
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024.
prnewswire.com
6 months ago
CRANFORD, N.J. , Nov. 25, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person Type C meeting with the U.S. Food and Drug Administration (FDA).
See all news
